deaths (OS)

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 certainty unassessable-19%